Four years after Andreessen Horowitz raised its first bio fund, the VC shop is launching its third biotech- and healthcare-focused fund. At $750 million, Bio Fund III is a16z’s biggest fund of its kind yet, and it will bankroll early-stage companies, though General Partner Jorge Conde said it will “selectively” participate in more mature companies, too. 

For the rest of the article go to the following link: https://www.fiercebiotech.com/biotech/a16z-unveils-750m-fund-to-bankroll-startups-at-intersection-tech-medicine